SciClone Pharmaceuticals (Holdings) Limited announced unaudited consolidated financial results for the six months ended June 30, 2021. For the six months ended June 30, 2021, revenue was RMB 1,331,316,000 against RMB 1,160,982,000 for the same period of last year. Operating profit was RMB 698,474,000 against RMB 649,093,000 for the same period of last year. Profit for the period attributable to owners of the company was RMB 622,701,000 against RMB 597,110,000 for the same period of last year. Basic earnings per share was RMB 0.99 against RMB 1.10 for the same period of last year. Diluted earnings per share was RMB 0.92 against RMB 1.10 for the same period of last year.